focus -WSS

focus

author：knowledge 2025-09-30 18:53:54 - browse：47

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： What Henrietta Lacks settlement says about racism in medicine

WSS

Why Sanofi got shellacked over its spinoff

Paying for Covid pills will soon shift to insurers

Testing for cancer recurrence creates a new limbo for patients

Testing for cancer recurrence creates a new limbo for patients

OTC birth control: A brief history of over the counter pill design

Medtronic CEO on promising devices for diabetes, hypertension

focus

focus

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Microsoft strikes partnership with Duke Health to advance health AI

Hollywood unions extend contract negotiations for actors

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Drug repurposing or repositioning? The language matters

WHO may add ‘noma' to its list of neglected tropical diseases

Medical leaders decry Supreme Court decision on affirmative action

Telehealth options flood the market as retailers push virtual care

DIEP, the 'gold standard' of breast reconstruction, is under threat

What the cancer research community can learn from the Covid response

leisure time

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Senate panel to vote on hospitals, PBMs, prisoner care

Gilgo Beach: Police identify another victim in serial killing investigation

Maker of FluMist seeks to allow at

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Readout Newsletter: XBI biotech index, Akero Therapeutics

leisure time

focus

explore

Wikipedia